When Great Biology Meets Manufacturing Reality

During this segment of Cell & Gene Live, Solving Vector Yield Challenges in In Vivo CGT, Karen Kozarsky, Ph.D., President and CSO of Vector BioPartners, and Robert Bell, Ph.D., CSO of Ascidian Therapeutics, cover why elegant biological designs often struggle during process development and commercial scale up. Dr. Bell explains Ascidian's single AAV strategy, while Dr. Kozarsky discusses evaluating lower yielding vectors, tissue specific delivery, clinical dosing strategies, and the importance of stronger collaboration between biology and manufacturing teams.